The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Wall Street Journal on MSN1d
Amgen Obesity Drug Cut Weight In Closely Watched StudyA highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback